New Weight Loss Medication MariTide Shows Promise in Clinical Trials
A recent phase 2 clinical trial has revealed promising results for a new weight loss medication called MariTide. This once-a-month injection, also known as maridebart cafraglutide, has shown impressive efficacy in helping obese individuals shed excess weight.
The trial, which involved 465 obese participants, demonstrated that those taking MariTide lost between 12.3 to 16.2 percent of their body weight over the course of a year. In comparison, those on a placebo only lost 2.5 percent of their body weight.
For an additional 127 participants with both obesity and type 2 diabetes, the average weight loss over the year ranged from 8.4 to 12.3 percent of body weight, compared to just 1.7 percent for those on placebo treatments.
According to researchers from biopharmaceutical company Amgen and institutions across the US and Australia, MariTide presents a viable alternative to current weight loss medications like Ozempic that require weekly injections. The convenience of a monthly injection schedule could improve patient adherence to the treatment regimen.
Mechanism of Action
MariTide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, targeting GLP-1 receptors in the brain and pancreas to reduce appetite and regulate blood sugar levels. Additionally, the medication also interacts with glucose-dependent insulinotropic polypeptide (GIP) receptors, which play a role in insulin release, fat storage, metabolism, and appetite control.
Positive Outcomes and Side Effects
Despite its efficacy in promoting weight loss, MariTide was associated with gastrointestinal side effects such as vomiting and diarrhea in almost all participants. However, these side effects were less severe when the dose was gradually increased, suggesting a titration approach may be beneficial for future use.
Looking ahead, a phase 3 clinical trial is planned to assess MariTide’s long-term effectiveness and safety in a larger cohort over an extended period. Researchers are optimistic that the medication could lead to even greater weight loss beyond the initial year of treatment.
With obesity rates on the rise globally and the associated health risks, the development of innovative weight loss treatments like MariTide is crucial. The research findings have been published in the New England Journal of Medicine.
